Nifty
Sensex
:
:
10397.45
33844.86
37.05 (0.36%)
141.27 (0.42%)

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 500087 | NSE: CIPLA

597.25
-6.20 (-1.03%)
21-Feb-2018 | 3:53PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 607.00
  • 607.75
  • 589.25
  • 603.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 1409590
  • 8418.78
  • 663.40
  • 480.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,458.91
  • 41.41
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 51,947.36
  • 0.33%
  • 3.54

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 37.26%
  • 3.19%
  • 17.70%
  • FII
  • DII
  • Others
  • 0.66%
  • 14.48%
  • 26.71%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Net Sales
3,913.82
3,647.21
7.31%
4,082.41
3,751.02
8.83%
3,525.05
3,593.72
-1.91%
3,582.00
3,266.54
9.66%
Expenses
3,095.16
2,969.56
4.23%
3,278.02
3,070.31
6.77%
2,878.59
2,982.75
-3.49%
3,075.76
3,047.58
0.92%
EBITDA
818.66
677.65
20.81%
804.39
680.71
18.17%
646.46
610.97
5.81%
506.24
218.96
131.20%
EBIDTM
20.92%
18.58%
19.70%
18.15%
18.34%
17.00%
14.13%
6.70%
Other Income
52.93
153.49
-65.52%
113.33
27.23
316.20%
151.38
25.20
500.71%
22.79
54.74
-58.37%
Interest
9.15
59.33
-84.58%
42.02
35.16
19.51%
27.86
31.34
-11.10%
33.40
36.76
-9.14%
Depreciation
522.35
257.74
102.67%
302.22
229.18
31.87%
213.43
160.81
32.72%
632.19
141.43
347.00%
PBT
340.09
514.07
-33.84%
573.48
443.60
29.28%
556.55
444.02
25.34%
-136.56
95.51
-
Tax
-64.23
128.27
-
137.42
71.90
91.13%
130.77
70.81
84.68%
-75.70
-3.90
-
PAT
404.32
385.80
4.80%
436.06
371.70
17.32%
425.78
373.21
14.09%
-60.86
99.41
-
PATM
10.33%
10.58%
10.68%
9.91%
12.08%
10.39%
-1.70%
3.04%
EPS
4.98
4.66
6.87%
5.25
4.41
19.05%
5.08
4.54
11.89%
-0.77
1.01
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
15,103.28
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
4,010.38
Net Sales Growth
5.92%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
23.69%
 
Cost Of Goods Sold
5,423.63
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
2,054.39
Gross Profit
9,679.65
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
1,955.99
GP Margin
64.09%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
48.77%
Total Expenditure
12,327.53
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
3,377.91
Power & Fuel Cost
-
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
74.69
% Of Sales
-
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
1.86%
Employee Cost
-
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
186.47
% Of Sales
-
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
4.65%
Manufacturing Exp.
-
1,704.79
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
509.42
% Of Sales
-
11.84%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
12.70%
General & Admin Exp.
-
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
221.14
% Of Sales
-
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
5.51%
Selling & Distn. Exp.
-
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
282.21
% Of Sales
-
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
7.04%
Miscellaneous Exp.
-
133.52
83.99
497.67
441.10
355.12
194.07
111.96
185.92
323.64
282.21
% Of Sales
-
0.93%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
1.24%
EBITDA
2,775.75
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
632.47
EBITDA Margin
18.38%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
15.77%
Other Income
340.43
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
339.28
Interest
112.43
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
17.52
Depreciation
1,670.19
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
116.26
PBT
1,333.56
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
837.97
Tax
128.26
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
136.93
Tax Rate
9.62%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
16.34%
PAT
1,205.30
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
PAT before Minority Interest
1,174.90
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
Minority Interest
-30.40
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.98%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
17.48%
PAT Growth
-2.02%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
9.98%
 
Unadjusted EPS
14.54
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92
9.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,525.42
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
3,755.17
Share Capital
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
155.46
Total Reserves
12,302.48
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
3,599.71
Non-Current Liabilities
4,513.35
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
689.60
Secured Loans
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
14.09
Unsecured Loans
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
526.36
Long Term Provisions
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
0.00
Current Liabilities
3,308.07
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
1,287.80
Trade Payables
1,571.14
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
533.51
Other Current Liabilities
923.79
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
337.48
Short Term Borrowings
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
0.00
Short Term Provisions
345.91
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
416.81
Total Liabilities
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57
Net Block
9,472.00
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
1,661.36
Gross Block
11,305.32
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
2,201.79
Accumulated Depreciation
1,580.49
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
540.43
Non Current Assets
11,979.00
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
1,898.51
Capital Work in Progress
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
233.12
Non Current Investment
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
4.03
Long Term Loans & Adv.
477.35
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
0.00
Other Non Current Assets
209.31
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
0.00
Current Assets
8,806.07
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
3,834.06
Current Investments
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
89.45
Inventories
3,485.28
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
1,120.49
Sundry Debtors
2,497.42
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
1,406.49
Cash & Bank
624.21
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Other Current Assets
1,361.77
437.05
145.60
35.50
468.31
622.17
726.59
2,537.33
1,821.13
1,137.93
Short Term Loans & Adv.
968.64
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
1,103.44
Net Current Assets
5,498.00
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
2,546.26
Total Assets
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,382.37
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
367.00
PBT
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
837.97
Adjustment
1,379.75
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
104.48
Changes in Working Capital
230.72
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
-404.47
Cash after chg. in Working capital
2,832.64
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
537.98
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
-170.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,312.65
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
-674.41
Net Fixed Assets
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
-562.01
Net Investments
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
23.05
Others
-393.51
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
-135.45
Cash from Financing Activity
-1,323.85
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
254.83
Net Cash Inflow / Outflow
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
-52.58
Opening Cash & Equivalents
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
132.28
Closing Cash & Equivalent
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
154.92
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
48.20
ROA
4.98%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
13.82%
ROE
8.73%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
20.11%
ROCE
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
22.40%
Fixed Asset Turnover
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
2.05
Receivable days
60.55
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
108.37
Inventory Days
90.98
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
93.41
Payable days
44.80
48.67
52.17
44.93
48.58
50.51
56.11
69.48
59.02
46.55
Cash Conversion Cycle
106.73
109.38
112.14
107.41
113.72
123.59
128.78
144.01
150.98
155.23
Total Debt/Equity
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
0.14
Interest Cover
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15
48.83

News Update:


  • Cipla’s Q3 consolidated net profit up by 5%
    7th Feb 2018, 14:28 PM

    Total consolidated income of the company increased by 4.37% at Rs 3966.75 crore for quarter under review

    Read More
  • Cipla - Quarterly Results
    7th Feb 2018, 14:00 PM

    Read More
  • Cipla receives USFDA’s approval for Generic Viread Tablets
    29th Jan 2018, 09:02 AM

    The product will be available for commercial shipment in the U.S. immediately

    Read More
  • Cipla’s arm enters into agreement to sell 100% stake in Cipla Croatia
    1st Dec 2017, 09:04 AM

    This step has been taken in order to align with company’s strategy to operate via a B2B model in Europe

    Read More
  • Cipla launches Q-TIB product globally
    30th Nov 2017, 14:00 PM

    The company has received an approval for its product Q-TIB from World Health Organisation

    Read More
  • Cipla’s arm to expand consumer health business: Report
    30th Nov 2017, 09:37 AM

    It is looking to expand the business through more in-house launches and brand acquisitions in the coming quarters

    Read More
  • Cipla receives final approval for generic Dacogen
    20th Nov 2017, 09:01 AM

    Dacogen and its generic equivalents had US sales of approximately $180 million for the 12-month period ending September 2017

    Read More
  • Cipla receives final approval for generic Pulmicort Respules
    17th Nov 2017, 09:02 AM

    It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.